




INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>					
				Application Number		09/910059		11000 U.S. PTO 09/910059  07/23/01	
				Filing Date					
				First-Named Inventor		Clive Graham COPLEY			
				Group Art Unit					
				Examiner Name		ATTALP 42 # 1 1/2			
Sheet	1	of	3	Attorney Docket Number		1991-209			
U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
		Number	Kind Code (if known)						
FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶		
		Office	Number	Kind Code (if known)					
LA	AA	EP	633,029		Cancer Research Campaign Technology Ltd.	10-11-1995			
↓	AB	WO	95/15341		Cancer Research Campaign Technology Ltd.	06-08-1995			
	AC	WO	96/11013		Immunomedics	04-18-1996			
↓	AD	WO	92/01059		Celltech Ltd.	01-23-1992			
LA	AE	WO	94/25585		Genpharm International Inc.	11-10-1994			
Examiner Signature					Date Considered	4/24/03			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/9/0059
				Filing Date	
				First Named Inventor	Clive Graham Copley
				Group Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	1991-209
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
LN	AF	Abraham, "Screening and kinetic analysis of recombinant anti-CEA antibody fragments," <i>Journal of Immunological Methods</i> , 183, 1995, pp. 119-125, Elsevier Science B.V.			
	AG	Accolla, "Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines," <i>Proc. Natl. Acad. Sci.</i> , 77, 1980, pp. 563-566			
	AH	Banjo, "Intermolecular heterogeneity of the Carcinoembryonic Antigen," <i>Cancer Research</i> , 34, August 1974, pp. 2114-2121			
	AI	Chandrasekaran, "Isolation and Structures of the Oligosaccharaide Units of Carcinoembryonic Antigen," <i>The Journal of Biological Chemistry</i> , 258, 1983, pp. 7213-7222, U.S.A.			
	AJ	Chournoyer, "Transcription of Genes of the Carcinoembryonic Antigen Family in Malignant and Nonmalignant Human Tissues," <i>Cancer Research</i> , 48, 1988, pp. 3153-3157			
	AK	Durbin, "An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3," <i>Proc. Natl. Acad. Sci.</i> , 91, 1994, pp. 4313-4317			
	AL	Haggarty, "Epitopes of Carcinoembryonic Antigen Defined by Monoclonal Antibodies Prepared from Mice Immunized with Purified Carcinoembryonic Antigen or HCT-8R Cells," <i>Cancer Research</i> , 46, 1986, pp. 300-309			
	AM	Hammarstrom, "Antigenic Sites in Caracinoembryonic Antigen," <i>Cancer Research</i> , 49, 1989, pp. 4852-4858			
	AN	Hansen, "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <i>Cancer</i> , 71, June 1993, pp. 3478-3485			
	AO	Hedin, "Specificities and binding properties of eight monoclonal antibodies against carcinoembryonic antigen," <i>Molecular Immunology</i> , 19, 1982, pp. 1641-1648, Pergamon Press Ltd., U.K.			
CA	AP	Hefta, "Expression of Caracinoembryonic Antigen and Its Predicted Immunoglobulin-like Domains in HeLa Cells for Epitope Analysis," <i>Cancer Research</i> , 52, October 1992, 5647-5655			
Examiner Signature				Date Considered	4/24/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/910059
				Filing Date	
				First Named Inventor	Clive Graham Copley, et al.
				Group Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	1991-209
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
LM	AQ	Konstadoulakis, "The Presence of Anti-Carcinoembryonic Antigen (CEA) Antibodies in the Sera of Patients with Gastrointestinal Malignancies," <i>Journal of Clinical Immunology</i> , 14, 1994, pp. 310-313			
	AR	Kuroki, "Purification and Characterization of Carcinoembryonic Antigen-related Antigens in Normal Adult Feces," <i>Cancer Research</i> , 41, February 1981, 713-718			
	AS	Kupchik, Monoclonal Antibodies to Carcinoembryonic Antigen Produced by Somatic Cell Fusion," <i>Cancer Research</i> , 41, September 1981, pp. 3306-3310			
	AT	Oikawa, "Primary Structure of Human Carcinoembryonic Antigen (CEA) Deduced from cDNA Sequence," <i>Biochemicals and Biophysical Research Communications</i> , 142, 1987, pp. 511-518			
	AU	Rogers, "Somatic-Cell Hybrids Producing Antibodies Against CEA," <i>Br. J. Cancer</i> , 43, 1981, pp. 1-4			
	AV	Thomas, "A Peptide Sequence on Carcinoembryonic Antigen Binds to a 80kD Protein on Kupffer Cells," <i>Biochemicals and Biophysical Research Communications</i> , 188, 1992, pp. 671-677			
	AW	D. Blakely et al., "Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs," <i>British Journal of Cancer</i> , Nov. 1995, pages 1083-1088, Vol. 72, No. 5, Basingstoke, GB			
	AX	M. Michael et al., "In vitro and in vivo characterization of a recombinant carboxypeptidase G2:anti-CEA scFv fusion protein," <i>Immunotechnology</i> , 1996, pages 47-57, vol. 2, no. 1, Amsterdam, NL.			
	AY	S. Leung et al., "Bacterial expression of a keptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment," <i>Cancer Research</i> , Dec. 1, 1995, pages 5968S-5972S, vol. 55, no. 23, suppl., Baltimore, MD, USA			
	AZ	K. Bosslet et al., "Tumor-selective prodrug activation by fusion protein-mediated catalysis," <i>Cancer Research</i> , April 1, 1994, pages 2151-2159, vol. 54, no. 7, Baltimore, MD, USA			
Examiner Signature				Date Considered	4/24/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.